Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIODESIX INC Director's Dealing 2024

May 24, 2024

34472_dirs_2024-05-23_c7b69fe0-bf64-464c-b21e-df5bea1a6a98.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIODESIX INC (BDSX)
CIK: 0001439725
Period of Report: 2024-05-21

Reporting Person: PATIENCE JOHN (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-05-23 Common Stock M 217400 Acquired 4829611 Indirect

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-05-21 Restricted Stock Units $ A 46686 Acquired Common Stock (46686) Direct
2024-05-21 Stock Options (Right to Buy) $1.57 A 37050 Acquired 2034-05-20 Common Stock (37050) Direct
2024-05-23 Series A Non-Voting Convertible Preferred Stock $ M 5435 Disposed Common Stock (217400) Indirect

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 337926 Direct
Common Stock 2078298 Indirect
Common Stock 52988 Indirect

Footnotes

F1: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024.

F2: The Reporting Person is the sole trustee of John Patience Living Trust (July 23, 1993).

F3: The Reporting Person is the sole general partner of Patience Enterprises LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F4: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Common Stock.

F5: These RSUs will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period.

F6: This option will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, this option will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period.